MA50094A - Méthodes de traitement des troubles du sommeil, des perturbations du sommeil et de symptômes associés à l'aide de compositions d'aminostérol - Google Patents

Méthodes de traitement des troubles du sommeil, des perturbations du sommeil et de symptômes associés à l'aide de compositions d'aminostérol

Info

Publication number
MA50094A
MA50094A MA050094A MA50094A MA50094A MA 50094 A MA50094 A MA 50094A MA 050094 A MA050094 A MA 050094A MA 50094 A MA50094 A MA 50094A MA 50094 A MA50094 A MA 50094A
Authority
MA
Morocco
Prior art keywords
methods
related symptoms
sleep
treating
disturbances
Prior art date
Application number
MA050094A
Other languages
English (en)
Inventor
Denise Barbut
Michael Zasloff
Original Assignee
Enterin Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Enterin Inc filed Critical Enterin Inc
Publication of MA50094A publication Critical patent/MA50094A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/223—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of alpha-aminoacids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/60—Fish, e.g. seahorses; Fish eggs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Otolaryngology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Inorganic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MA050094A 2017-09-08 2018-09-05 Méthodes de traitement des troubles du sommeil, des perturbations du sommeil et de symptômes associés à l'aide de compositions d'aminostérol MA50094A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762556164P 2017-09-08 2017-09-08

Publications (1)

Publication Number Publication Date
MA50094A true MA50094A (fr) 2020-07-15

Family

ID=65635152

Family Applications (1)

Application Number Title Priority Date Filing Date
MA050094A MA50094A (fr) 2017-09-08 2018-09-05 Méthodes de traitement des troubles du sommeil, des perturbations du sommeil et de symptômes associés à l'aide de compositions d'aminostérol

Country Status (4)

Country Link
US (2) US11083735B2 (fr)
EP (1) EP3678671A4 (fr)
MA (1) MA50094A (fr)
WO (1) WO2019050903A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11083735B2 (en) * 2017-09-08 2021-08-10 Enterin, Inc. Methods for treating sleep disorders, sleep disturbances, and related symptoms using aminosterol compositions
WO2019190950A1 (fr) * 2018-03-27 2019-10-03 Enterin, Inc. Méthodes et compositions de traitement d'hallucinations et d'états associés à celles-ci
US11464789B2 (en) 2018-08-03 2022-10-11 Enterin, Inc. Aminosterol compositions and methods of using the same for treating schizophrenia
US20210315907A1 (en) * 2018-08-03 2021-10-14 Enterin, Inc, Compositions and methods for treating brain-gut disorders
US20230125585A1 (en) * 2019-08-02 2023-04-27 Enterin, Inc. Dosing protocols and regimens for aminosterol treatment
KR102417541B1 (ko) * 2020-11-05 2022-07-06 주식회사 휴서카디안 피드백 기반의 일주기 리듬 관리 장치 및 방법
AU2022301046B2 (en) * 2021-06-27 2025-01-02 The Jackson Laboratory Visual determination of sleep states
WO2024232931A1 (fr) * 2023-05-11 2024-11-14 Yon Doo Ough Appareil et procédé de délivrance et d'administration sans contact de magnésium en tant que médicament

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5192756A (en) 1992-03-18 1993-03-09 The Children's Hospital Of Pennsylvania Aminosterol antibiotic
WO1994020520A1 (fr) 1993-03-10 1994-09-15 Magainin Pharmaceuticals Inc. Derives steroidiens, compositions pharmaceutiques contenant ces derives steroidiens et utilisation de ces derniers comme antibiotiques ou desinfectants
US5856535A (en) 1994-08-18 1999-01-05 Magainin Pharmaceuticals, Inc. Aminosterol ester compounds
US5840740A (en) 1995-06-07 1998-11-24 Magainin Pharmaceuticals Inc. Aminosterol compounds and a method of treating infection using the aminosterol compounds
AU3512595A (en) 1994-09-13 1996-03-29 Magainin Pharmaceuticals, Inc. Method for inhibiting sexually transmitted diseases using magaining antimicrobials or squalamine compounds
US5834453A (en) 1995-05-30 1998-11-10 Lehigh University Methods for the manufacture and use of antimicrobial sterol conjugates
AU723663C (en) * 1995-06-07 2001-11-01 Magainin Pharmaceuticals, Inc. Aminosterol compounds useful as inhibitors of the sodium/proton exchanger (NHE), pharmaceutical methods and compositions employing such inhibitors, and processes for evaluating the NHE-inhibitory efficacy of compounds
US5795885A (en) 1995-06-07 1998-08-18 Magainin Pharmaceuticals Inc. Method of inhibiting profileration of cells by administering an aminosterol compound
US5847172A (en) 1995-06-07 1998-12-08 Magainin Pharmaceuticals Inc. Certain aminosterol compounds and pharmaceutical compositions including these compounds
US5763430A (en) 1995-06-07 1998-06-09 Magainin Pharmaceuticals Inc. Method of treating a viral infection by administering a steroid compound
US6143738A (en) 1995-06-07 2000-11-07 Magainin Pharmaceuticals, Inc. Therapeutic uses for an aminosterol compound
US5874597A (en) 1995-06-07 1999-02-23 Magainin Pharmaceuticals, Inc. Certain aminosterol compounds and pharmaceutical compositions including these compounds
US5792635A (en) 1995-06-07 1998-08-11 Magainin Pharmaceuticals, Inc. Method of inhibiting the sodium/proton exchanger NHE3 and method of inhibiting growth by administering squalamine
US5840936A (en) 1995-06-07 1998-11-24 Magainin Pharmaceuticals Inc. Aminosterol compounds useful as inhibitors of the sodium/proton exchanger (NHE)
US5994336A (en) 1995-06-07 1999-11-30 Magainin Pharmaceuticals Inc. Method of inhibiting proliferation of cells by administering an aminosterol compound
US5744453A (en) 1996-01-05 1998-04-28 Mintz; Clifford S. Polyamine conjugates for treatment of infection
US6596712B2 (en) 1996-04-26 2003-07-22 Genaera Corporation Treatment of carcinomas using squalamine in combination with other anti-cancer agents or modalities
PT910382E (pt) 1996-04-26 2003-10-31 Genaera Corp Esqualamina em combinacao com outros agentes anti-cancro para o tratamento de tumores
WO2000009137A2 (fr) 1998-08-12 2000-02-24 Magainin Pharmaceuticals, Inc. Composes aminosteroliques et utilisations correspondantes
ES2732251T3 (es) 2005-04-25 2019-11-21 Enterin Inc Dilactato de escualamina cristalino
WO2007064691A1 (fr) 2005-12-02 2007-06-07 Nabil Habib Lab Traitement du cancer et d'autres maladies
MX2008013592A (es) * 2006-04-21 2009-03-06 Genaera Corp Induccion de perdida de peso e inhibicion selectiva de la proteina tirosina fosfatasa 1b.
WO2009032321A2 (fr) 2007-09-06 2009-03-12 Genaera Corporation Procédé de traitement du diabète
US8729058B2 (en) 2009-10-27 2014-05-20 Michael Zasloff Methods and compositions for treating and preventing viral infections
MX367255B (es) * 2012-04-20 2019-08-12 Ohr Pharmaceutical Inc Aminoesteroides para tratamiento de una enfermedad asociada con proteina fosfatasa 1b (ptp1b).
US10040817B2 (en) * 2013-10-03 2018-08-07 Enterin Laboratories, Inc. Methods and compositions for stimulation of the intestinal enteroendocrine system for treating diseases or conditions related to the same
US11083735B2 (en) * 2017-09-08 2021-08-10 Enterin, Inc. Methods for treating sleep disorders, sleep disturbances, and related symptoms using aminosterol compositions
WO2019190950A1 (fr) * 2018-03-27 2019-10-03 Enterin, Inc. Méthodes et compositions de traitement d'hallucinations et d'états associés à celles-ci

Also Published As

Publication number Publication date
US20210338691A1 (en) 2021-11-04
EP3678671A1 (fr) 2020-07-15
EP3678671A4 (fr) 2022-12-07
WO2019050903A1 (fr) 2019-03-14
US11083735B2 (en) 2021-08-10
US20190091241A1 (en) 2019-03-28

Similar Documents

Publication Publication Date Title
MA50094A (fr) Méthodes de traitement des troubles du sommeil, des perturbations du sommeil et de symptômes associés à l'aide de compositions d'aminostérol
EP3180022A4 (fr) Cassette d'expression améliorée pour le conditionnement et l'expression de variantes du facteur viii pour le traitement des troubles de l'hémostase
EP3423047A4 (fr) Compositions d'agonistes sélectifs du récepteur cb2 pour le traitement des troubles mentaux
EP3344274A4 (fr) Méthodes et compositions pour le traitement d'états pathologiques associés à des réponses inflammatoires anormales
EP3377118A4 (fr) Méthodes pour traiter la maladie d'alzheimer et des troubles associés
EP3465212A4 (fr) Régulation du microbiote intestinal pour le traitement de troubles neurodégénératifs
MA51056A (fr) Compositions et méthodes pour le traitement d'affections métaboliques
EP2986296A4 (fr) Traitement et suivi du pronostic des troubles de prolifération à l'aide d'inhibiteurs de la voie hedgehog
EP3445352A4 (fr) Compositions pour le traitement de troubles liés à l'hyperkératose
EP3445451A4 (fr) Compositions et méthodes pour le traitement de troubles lysosomaux et de troubles caractérisés par un dysfonctionnement lysosomal
EP2911664A4 (fr) Polythérapies pour le traitement de la maladie d'alzheimer et des troubles associés
EP3692023A4 (fr) Composés benzothiazol et méthodes d'utilisation de ceux-ci pour traiter des troubles neurodégénératifs
MA52861A (fr) Méthodes et compositions pour le traitement de l'apnée du sommeil
MA44426B1 (fr) Compositions et méthodes pour diminier l'expression de tau
EP3368088C0 (fr) Compositions et méthodes pour le traitement de troubles du peroxisome et de leucodystrophies
MA54150A (fr) Compositions et méthodes de traitement de troubles dépendant des oestrogènes
EP3291693A4 (fr) Régime alimentaire imitant et favorisant le jeûne pour le traitement de l'hypertension et des troubles lipidiques
EP3902536A4 (fr) Compositions et méthodes de traitement de troubles neurodégénératifs
EP3644983A4 (fr) Compositions et méthodes de traitement ou de prévention d'affections pulmonaires fibreuses
EP3773491A4 (fr) Méthodes de traitement de troubles associés à l'apoe4/4
EP3595689A4 (fr) Méthodes et compositions pour traiter l'obésité, l'inflammation ou des troubles métaboliques avec des bactériophages
EP3749322A4 (fr) Composés et méthodes de traitement d'une dépendance et de troubles associés
MA42985A (fr) Traitement de troubles liés à l'acide biliaire
EP3920898A4 (fr) Méthodes et compositions pour le traitement de l'apnée du sommeil
EP3442554A4 (fr) Compositions et méthodes pour le traitement de troubles associés à la néovascularisation